{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:23:23Z","timestamp":1786469003422,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcte.2023.100320","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T21:23:57Z","timestamp":1687641837000},"page":"100320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes"],"prefix":"10.1016","volume":"33","author":[{"given":"Fabian","family":"Lurquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Preumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1464-5491.2003.00924.x","article-title":"Cystic fibrosis-related diabetes","volume":"20","author":"Mackie","year":"2003","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jcte.2023.100320_b0015","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/clinem\/dgaa932","article-title":"Glucose Tolerance Stages in Cystic Fibrosis Are Identified by a Unique Pattern of Defects of Beta-Cell Function","volume":"106","author":"Piona","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jcte.2023.100320_b0020","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jcte.2023.100320_b0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107845","article-title":"Effect of CFTR modulator therapy on cystic fibrosis-related diabetes","volume":"35","author":"Gaines","year":"2021","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcte.2023.100320_b0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcte.2023.100320_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-Term Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0050","doi-asserted-by":"crossref","first-page":"17231","DOI":"10.1038\/s41598-017-17404-z","article-title":"Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes","volume":"7","author":"Bogdani","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jcte.2023.100320_b0055","first-page":"E200","article-title":"CFTR silencing in pancreatic \u03b2-cells reveals a functional impact on glucose-stimulated insulin secretion and oxidative stress response","volume":"310","author":"Ntimbane","year":"2016","journal-title":"Am J Physiol Metab"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms5420","article-title":"Glucose-induced electrical activities and insulin secretion in pancreatic islet \u03b2-cells are modulated by CFTR","volume":"5","author":"Guo","year":"2014","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jcte.2023.100320_b0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI insight"},{"issue":"10","key":"10.1016\/j.jcte.2023.100320_b0070","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1210\/en.2017-00282","article-title":"Glucose-Sensitive CFTR Suppresses Glucagon Secretion by Potentiating KATP Channels in Pancreatic Islet \u03b1 Cells","volume":"158","author":"Huang","year":"2017","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jcte.2023.100320_b0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor\u2013ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2023.100320_b0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2023.100320_b0085","first-page":"100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.jcte.2023.100320_b0095","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201405-0882LE","article-title":"Resolution of Cystic Fibrosis\u2013related Diabetes with Ivacaftor Therapy","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcte.2023.100320_b0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.jcte.2023.100320_b0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2017.11.016","article-title":"Effect of Lumacaftor\/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients","volume":"17","author":"Thomassen","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2018.07.010","article-title":"Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor","volume":"18","author":"Li","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcte.2023.100320_b0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcte.2023.100320_b0120","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"14","key":"10.1016\/j.jcte.2023.100320_b0125","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcte.2023.100320_b0130","first-page":"100311","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcte.2023.100320_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros Published online"},{"issue":"2_suppl","key":"10.1016\/j.jcte.2023.100320_b0140","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3132\/dvdr.2007.019","article-title":"Diabetic macro- and microvascular disease in type 2 diabetes","volume":"4","author":"Hermans","year":"2007","journal-title":"Diabetes Vasc Dis Res"},{"issue":"10","key":"10.1016\/j.jcte.2023.100320_b0145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcte.2023.100320_b0150","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/0026-0495(79)90146-X","article-title":"Insulin deficiency and insulin resistance interaction in diabetes: Estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations","volume":"28","author":"Turner","year":"1979","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.jcte.2023.100320_b0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.jcte.2023.100320_b0160","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0165","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jcte.2023.100320_b0170","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.diabet.2009.08.001","article-title":"Dietary cassava, \u03b2-cell function and hyperbolic product loss rate in type 2 diabetes patients from South Kivu","volume":"36","author":"Manwa","year":"2010","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.jcte.2023.100320_b0175","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/dc06-1915","article-title":"Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene \u0394F508 mutation","volume":"30","author":"Preumont","year":"2007","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2021.05.010","article-title":"HOMA indices as screening tests for cystic fibrosis-related diabetes","volume":"21","author":"Toin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcte.2023.100320_b0185","doi-asserted-by":"crossref","DOI":"10.1515\/jpem-2016-0184","article-title":"Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: is the oral glucose tolerance test still the standard?","volume":"30","author":"Mainguy","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jcte.2023.100320_b0190","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1515\/jpem-2017-0122","article-title":"Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?","volume":"30","author":"Boudreau","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0195","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jcf.2009.08.007","article-title":"Validation of insulin secretion indices in cystic fibrosis patients","volume":"8","author":"Hammana","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"19","key":"10.1016\/j.jcte.2023.100320_b0200","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcte.2023.100320_b0205","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.S221","article-title":"Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation","volume":"51","author":"Mari","year":"2002","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jcf.2016.04.004","article-title":"Variation of glucose tolerance in adult patients with cystic fibrosis: What is the potential contribution of insulin sensitivity?","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcte.2023.100320_b0215","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol Published online"},{"issue":"10","key":"10.1016\/j.jcte.2023.100320_b0220","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-5491.1995.tb00399.x","article-title":"The 30 Minute Insulin Incremental Response in an Oral Glucose Tolerance Test as a Measure of Insulin Secretion","volume":"12","author":"Wareham","year":"1995","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.jcte.2023.100320_b0225","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jcte.2023.100320_b0230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2021.11.011","article-title":"Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies","volume":"21","author":"Caterini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2023.100320_b0235","doi-asserted-by":"crossref","unstructured":"Nielsen BU, Faurholt-Jepsen D, Oturai PS, et al. Associations Between Glucose Tolerance, Insulin Secretion, Muscle and Fat Mass in Cystic Fibrosis. Clin Med Insights Endocrinol Diabetes. 2021. 14. 11795514211038260. doi:10.1177\/11795514211038259.","DOI":"10.1177\/11795514211038259"},{"issue":"11","key":"10.1016\/j.jcte.2023.100320_b0240","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3390\/healthcare10112205","article-title":"Effectiveness of Physical Exercise Interventions on Pulmonary Function and Physical Fitness in Children and Adults with Cystic Fibrosis: A Systematic Review with Meta-Analysis","volume":"10","author":"Garc\u00eda-P\u00e9rez-de-Sevilla","year":"2022","journal-title":"Healthcare"},{"issue":"5","key":"10.1016\/j.jcte.2023.100320_b0245","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","article-title":"Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor","volume":"21","author":"Rysgaard","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcte.2023.100320_b0250","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221462372300008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221462372300008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:57:36Z","timestamp":1762005456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221462372300008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"alternative-id":["S221462372300008X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2023.100320","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2023.100320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100320"}}